Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
06
2019
accepted:
19
11
2019
pubmed:
23
11
2019
medline:
28
4
2021
entrez:
23
11
2019
Statut:
epublish
Résumé
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of CAR T cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications including cytopenias and B-cell aplasia, nursing and psychological support for patients, long-term follow-up, post-authorization safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.
Identifiants
pubmed: 31753925
pii: haematol.2019.229781
doi: 10.3324/haematol.2019.229781
pmc: PMC7012497
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-316Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Blood. 2019 Jun 27;133(26):2800-2802
pubmed: 31101626
Biol Blood Marrow Transplant. 2016 Oct;22(10):1736-1737
pubmed: 27543158
Hematol Oncol. 2018 Feb;36(1):324-327
pubmed: 28971493
Nat Rev Clin Oncol. 2019 Jan;16(1):45-63
pubmed: 30082906
Blood. 2018 Jan 4;131(1):121-130
pubmed: 29038338
Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85
pubmed: 30576834
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):559-64
pubmed: 25696911
Hum Gene Ther. 2018 May;29(5):559-568
pubmed: 29620951
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Mol Ther. 2017 Oct 4;25(10):2245-2253
pubmed: 28803861
Science. 2017 Jun 16;356(6343):1112-1113
pubmed: 28619895
J Exp Med. 2005 Oct 3;202(7):907-12
pubmed: 16203864
Blood. 2013 Dec 12;122(25):4129-39
pubmed: 24055823
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Blood. 2019 Sep 12;134(11):860-866
pubmed: 31320380
Curr Res Transl Med. 2018 May;66(2):62-64
pubmed: 29656949
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643233
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
Brain. 2019 May 1;142(5):1334-1348
pubmed: 30891590
Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71
pubmed: 22178693
Oncoimmunology. 2017 Mar 28;6(5):e1308618
pubmed: 28638731
Biochem Biophys Res Commun. 1987 Dec 31;149(3):960-8
pubmed: 3122749
Blood. 2019 Apr 25;133(17):1876-1887
pubmed: 30782611
J Clin Invest. 2016 Sep 1;126(9):3363-76
pubmed: 27482888
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Pharmacotherapy. 2017 Mar;37(3):334-345
pubmed: 28079265
J Clin Oncol. 2017 Sep 10;35(26):3010-3020
pubmed: 28715249
Curr Res Transl Med. 2019 Aug;67(3):79-88
pubmed: 31182380
Blood. 2019 Apr 11;133(15):1652-1663
pubmed: 30728140
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
Bone Marrow Transplant. 2010 Oct;45(10):1546-52
pubmed: 20190846
Br J Haematol. 2016 Mar;172(5):685-98
pubmed: 26791002
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8
pubmed: 2513569
Drugs. 2017 Mar;77(3):237-245
pubmed: 28110394
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Curr Res Transl Med. 2018 May;66(2):35-36
pubmed: 29685844
Blood. 2015 Jun 25;125(26):4017-23
pubmed: 25999455
Biol Blood Marrow Transplant. 2019 Apr;25(4):e123-e127
pubmed: 30586620
Bull Cancer. 2020 Jan;107(1S):S12-S17
pubmed: 31202556
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
Bull Cancer. 2017 Dec;104(12S):S43-S58
pubmed: 29174320
Clin Cancer Res. 2019 Jan 1;25(1):358-368
pubmed: 30425092
Biol Blood Marrow Transplant. 2016 Oct;22(10):1851-1860
pubmed: 27318038
Oncoimmunology. 2015 May 26;4(11):e1027469
pubmed: 26451310
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Crit Care Med. 2014 Mar;42(3):656-63
pubmed: 24145848
Oncotarget. 2017 May 9;8(19):31368-31385
pubmed: 28404896
Curr Res Transl Med. 2018 May;66(2):43-49
pubmed: 29655961
Clin Adv Hematol Oncol. 2018 Oct;16(10):664-666
pubmed: 30543595
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Bull Cancer. 2019 Jan;106(1S):S102-S109
pubmed: 30661749
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Curr Res Transl Med. 2017 Sep;65(3):93-102
pubmed: 28988742
Clin Infect Dis. 2019 Aug 30;69(6):909-920
pubmed: 30520987
Lancet Oncol. 2015 Apr;16(4):e158
pubmed: 25846094
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Bone Marrow Transplant. 2011 Oct;46(10):1374-81
pubmed: 21132028
Haematologica. 2013 Nov;98(11):1726-31
pubmed: 23753028
Bone Marrow Transplant. 2017 Oct;52(10):1367-1371
pubmed: 28346416
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Curr Res Transl Med. 2018 May;66(2):57-58
pubmed: 29685843
Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670
pubmed: 29680516
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Immunotherapy. 2017 Jan;9(2):123-130
pubmed: 28128714
Curr Res Transl Med. 2018 May;66(2):50-52
pubmed: 29625831
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1012-1021
pubmed: 31175906
Best Pract Res Clin Haematol. 2017 Dec;30(4):336-340
pubmed: 29156206